Abstract Molecular subclassification is rapidly informing the clinical management of medulloblastoma. However, the disease remains associated with poor outcomes and therapyassociated late effects, and the majority of patients are not characterized by a validated prognostic biomarker. Here, we investigated the potential of epigenetic DNA methylation for disease subclassification, particularly in formalinfixed biopsies, and to identify biomarkers for improved therapeutic individualization. Tumor DNA methylation profiles were assessed, alongside molecular and clinical disease features, in 230 patients primarily from the SIOP-UKCCSG PNET3 clinical trial. We demonstrate by crossvalidation in frozen training and formalin-fixed test sets that medulloblastoma comprises four robust DNA methylation subgroups (termed WNT, SHH, G3 and G4), highly related to their transcriptomic counterparts, and which display distinct molecular, clinical and pathological disease characteristics. WNT patients displayed an expected favorable prognosis, while outcomes for SHH, G3 and G4 were equivalent in our cohort. MXI1 and IL8 methylation were identified as novel independent high-risk biomarkers in cross-validated survival models of non-WNT patients, and were validated using non-array methods. Incorporation of MXI1 and IL8 into current survival models significantly improved the assignment of disease risk; 46 % of patients could be classified as 'favorable risk' ([90 % survival) compared to 13 % using current models, while the high-risk group was reduced from 30 to 16 %. DNA methylation profiling enables the robust subclassification of four disease subgroups in frozen and routinely collected/archival formalin-fixed biopsy material, and the incorporation of DNA methylation biomarkers can significantly improve diseaserisk stratification. These findings have important implications for future risk-adapted clinical disease management.
Introduction
Medulloblastoma is the most common malignant pediatric brain tumor accounting for *10 % of childhood cancer deaths [37] . Current therapies are associated with variable survival outcomes and life-long cognitive and neuro-endocrine late effects in the majority of survivors [37] . Four consensus molecular disease variants characterized by their gene expression profiles are recognized [WNT, SHH (Sonic Hedgehog), Group 3 and Group 4], which display distinct clinical, pathological and molecular biologic features [48] . Robust biomarkers of favorable risk (b-catenin; WNT variant biomarker; *10 % of patients) and high risk (MYC amplification; *5 %) have been identified and validated in large/trials-based series [14-16, 36, 43] . These will be used to assign reduced treatments to WNT patients in first international clinical trials of biologically stratified therapy [37] . Despite these advances, the majority of medulloblastomas are not characterized by a validated prognostic biomarker and there remains a major unmet need for improved biological characterization to inform further therapeutic refinements, particularly in non-WNT patients.
Studies of DNA methylation profiles in adult brain tumors have demonstrated great promise in subclassifying disease [34] , and predicting clinical outcome; MGMT status predicts temozolomide sensitivity in glioblastoma [18] . However, studies of methylation events in medulloblastoma have been restricted to specific genes and/or modestly sized cohorts [1, 10, 20, 25, 27] . The wider role of DNA methylation patterns in medulloblastoma, and their clinical impact remain unknown.
We report a first examination of medulloblastoma DNA methylation patterns, using an extensive primary tumor cohort (n = 230) drawn primarily from the SIOP/UKCCSG PNET3 clinical trial [49] . We aimed to assess the ability of DNA methylation patterns to subclassify medulloblastoma, especially the validity of such subgrouping in formalinfixed/paraffin-embedded (FFPE) material. DNA methylation events are far more stable in comparison to RNA and methylation-based subgrouping may prove more amenable to clinical application in standard or archival biopsy material than RNA-based methods. Finally, we assessed the ability of individual methylation events to improve outcome prediction. We establish methylation events as clinically useful biomarkers and demonstrate how their incorporation into current risk-stratification schemes significantly improves the accuracy of survival prediction, allowing the re-classification of disease risk in the majority of patients and providing a potential basis for future therapeutic individualization aimed at improved outcomes and reduced late effects.
Materials and methods

DNA methylation profiling of medulloblastoma cohorts
DNA methylation events were profiled using the Illumina GoldenGate Cancer Panel I microarray [2] , according to manufacturer's instructions. This array measures the DNA methylation status at 1,505 loci in 807 genes, as a b score ranging from zero (fully unmethylated) to one (fully methylated). All samples were subjected to array quality control (QC) [4, 12] , alongside assessments of intra-and inter-replicate reproducibility, and quantitative accuracy, in extensive validation experiments versus independent bisulfite sequencing estimations of methylation status (Supplementary Methods, Supplementary Table S1 and Supplementary Figure S1 ).
230 primary medulloblastomas passed QC measures following array analysis. Patients were split into training [n = 100; DNA (n = 100) and RNA (n = 88) extracted from fresh-frozen tumor material] and test cohorts (n = 130; DNA from FFPE tissue, derived exclusively from patients enrolled on the International Society of Pediatric Oncology (SIOP)/United Kingdom Children's Cancer Study Group (UKCCSG) PNET3 clinical trial [49] ). Pathology was reviewed according to WHO criteria [28] , and metastatic (M) stage determined using Chang's criteria [6] . Prognostic models were developed using the combined cohort (n = 191) aged 3.0-16.0 years at diagnosis, representing 136 PNET3, and 55 training cohort patients. Cohort demographics are summarized in Table 1 .
Assessment of medulloblastoma molecular features
Established molecular correlates of medulloblastoma, encompassing markers of the WNT subgroup (CTNNB1 mutation [15] , chromosome 6 loss [8, 24] ), MYC and MYCN amplification [43] , and chromosome 17 status [8, 24] , were assessed as previously described. Medulloblastoma expression subgroup was assessed by immunohistochemistry [13, 15] , and using GeXP [44] and Nanostring [33] mRNA expression signature assays.
Bioinformatic and statistical analyses
A non-negative matrix factorization (NMF) [3] consensus clustering approach was used to identify robust and reproducible DNA methylation subgroups, and to validate these across training and test cohorts [47] (Supplementary Methods, Supplementary Figure S2 ). Pearson's correlations between methylation probe status and training cohort metagene values were calculated to identify subgroupspecific methylation changes.
The potential of methylation markers as prognostic biomarkers was assessed in non-WNT patients within the combined survival cohort (n = 163). Probes were first selected for variability and bimodality (Supplementary Methods). The prognostic potential of the 250 most bimodal probes was assessed using multivariate Cox proportional hazards models (Supplementary Methods).
First, we estimated the number of probes which could optimally improve the prognostic ability of predictive Cox The prognostic utilities of the selected methylation probe covariates were tested in univariate and multivariate Cox proportional hazards models. The methylation status of the selected prognostic methylation probes, as well as their relationship to neighboring CpG dinucleotides were validated using bisulfite sequencing with specific PCR primer sets (Supplementary Table S1), as previously described [26] . A clinically applicable risk-stratification scheme was developed following application of cutoffs to binarize the selected prognostic methylation probes. The predictive accuracy of the identified models was assessed using LOOCV [46] , and by calculating AUC [17] (Supplementary Methods).
All bioinformatic and statistical analyses were performed using R (v2.13) [39] . Survival analyses were performed using progression-free survival (PFS) times, defined as time elapsed from diagnosis to first event, which was tumor recurrence or progression.
Results
Medulloblastoma comprises four major DNA methylation subgroups
We first examined whether our tumor cohort (n = 230; Table 1 ) could be subclassified based on its DNA methylation patterns. The cohort was split into training and test The single tumor with extensive nodular (MBEN) pathology was included in the DN group. Percentages shown are based on patients with available data M-M0-1, M? M2-4, CLA classic, DN desmoplastic/nodular, LCA large-cell anaplastic, RTX radiotherapy, CTX chemotherapy, NA data not available, NC non-classifiable sets containing frozen tumor (n = 100) and FFPE-derived (n = 130; 9.4-17.1 years storage time) samples, respectively. This distinction was chosen deliberately to allow us to assess the efficacy of methylation subgrouping on archival diagnostic FFPE material, which cannot be subgrouped reliably using transcriptomic methods [33] . Metagenes were derived from the training set using NMF and clustered using K means. Different possible numbers of metagenes and clusters (both 2-6) were tested and crossvalidated by iterative resampling (i = 100), and the number of metagenes (four) and clusters (four) which gave the most consistent and robust classification was selected ( Fig. 1 ; Supplementary Figure S2 ). Next, metagene values derived from the training set were projected onto the test set of FFPE-derived samples, and a subgroup support vector machine (SVM) classifier trained on the frozen tumor cohort applied to assign subgroup membership within this test data set. 126 of 130 FFPE samples were assigned with high confidence, assessed using modified Brier scores [47] and metagene patterns were similar in both cohorts. Overall, 216/230 (94 %) tumors could be assigned to a subgroup, demonstrating a positive silhouette score (a measure of strength of clustering), and reproducible subgroup assignment (assigned to the same subgroup in [80 % iterative replicates). Using PCA to represent metagene values, each subgroup can be shown as distinct (Fig. 1) . A subset of samples (n = 10) could not be assigned reproducibly (i.e. in [80 % of iterative replicates) to any subgroup, or had negative silhouette scores indicating poorly clustered tumors (n = 4); these were designated non-classifiable (NC). NC tumors showed no significant molecular or clinico-pathological differences to the classified cohort (Fig. 1 ).
Medulloblastoma DNA methylation and gene expression subgroups are closely related To investigate the relationship between the identified methylation-dependent subgroups and previously reported gene expression subgroups [7, 22, 32, 48 , 51], we tested for significant association between DNA methylation subgroups and established expression subgroup markers in our combined training/test cohorts (Fig. 1) . One methylation subgroup was characterized by markers of WNT-pathway activation. 17/19 CTNNB1 mutations occurred in this subgroup alongside significant enrichment for chromosome 6 loss and nuclear accumulation of b-catenin (v 2 tests, all p \ 2 9 10 -16 ) [8, 13, 14] . A second subgroup showed significant enrichment for tumors with high protein expression of SHH markers (GAB1/YAP1) [13] . Consistent with the previous findings, G4 was enriched for loss of chromosome 17p relative to G3 (Fisher's exact test, p = 0.032), while MYC and MYCN amplifications were observed in all non-WNT subgroups. Importantly, a series of gene-specific hyper-and hypo-methylation events associated with each subgroup were identified ( Fig. 3 ; Supplementary Table S2) .
Finally, WNT subgroup tumors showed the favorable outcomes previously reported for WNT patients (identified by b-catenin IHC) within PNET3 [13] [14] [15] (Fig. 2 ; log-rank test, v 2 = 18.2, p = 0.001). However, despite the increased incidence of high-risk disease features in G3, all non-WNT subgroups showed equivalent PFS rates (Fig. 2) within this trials-based cohort. Of note, NC patients were associated with favorable outcomes.
MXI1 and IL8 methylation predict poor prognosis in non-WNT medulloblastomas
In view of the equivalent survival rates observed for all non-WNT methylomic subgroups, we next investigated the prognostic potential of individual DNA methylation events across the non-WNT subgroups. A cohort of 191 patients aged 3.0-16.0 at diagnosis based on the PNET3 clinical trial, including 163 non-WNT patients, was selected for analysis (Table 1) . Established prognostic features, previously identified in PNET3 and other trials (MYC family amplification, LCA histology, metastatic disease, WNT subgroup [14-16, 23, 42, 43, 50] ), were first validated and found to be significant, and PNET3 and non-PNET3 patients behaved equivalently within this cohort (Supplementary Figure S3 ). Females were additionally associated with improved survival, although their relationship to prognosis in previous studies has been inconsistent [9, 14, 43] . A Cox model with MYC or MYCN amplification, LCA histology and metastatic disease as covariates was thus considered to be the base survival model, representing the current clinical paradigm. We then systematically assessed the ability of methylation markers to augment the base model and improve risk prediction in non-WNT patients.
The 250 most bimodal methylation probes were assessed for their ability to significantly improve accuracy of survival prediction (Supplementary Figure S4) . To determine the optimal number of methylation probes to include in a putative risk model, methylation probes with univariate significance (p \ 0.05) were added, using forward likelihood ratio testing, to the base Cox model. Using LOOCV, the predicted survival of the excluded sample was recorded and the accuracy and significance of the crossvalidated risk models, after augmenting the base model with between 1 and 5 methylation probes, were evaluated by calculating survival accuracy at 5 years using a crossvalidated AUC (from ROC analysis) and p value.
Adding methylation probes to the base model always improved accuracy and significance of survival prediction, regardless of the number of added probes. Adding a combination of two methylation markers was chosen as optimal, and conferred a large increase in AUC relative to the base model, whilst maintaining low covariate p values and minimizing additional model complexity (Supplementary Figure S4) .
Having chosen the optimal number of genes to be added to the model, the genes were ranked according to their combinatorial ability to increase accuracy of survival prediction. This was evaluated as before, however, to correct for cohort and marker selection bias and calculate confidence intervals, the prediction accuracy (AUC) was now evaluated by biascorrected LOOCV (see Supplementary methods). We found that MXI1 (probe P1269; 163/163 folds) and IL8 (P83; 161/163 folds) were selected in [99 % of cross-validation Figure S4) . We next divided the MXI1 and IL8 methylation values into thirds (top third, beta C0.67, hyper-methylated; middle/lower thirds, beta \0.67, partially/hypo-methylated); this was compatible with the array-based distribution of methylation scores (Fig. 4) and the distribution of survival risk. MXI1 and IL8 methylation were both significantly associated with a worse prognosis in binary-classified logrank tests, and as both continuous and binary variables in univariate and multivariate Cox models, in non-WNT patients (Fig. 4) . Moreover, binary-classified, cross-validated survival models demonstrated similar predictive power to models constructed using continuous methylation variables (AUC = 0.776, 95 % CI 0.608-0.883, p = 0.005) (Fig. 4) .
Subgroups show differential patterns of IL8 and MXI1 methylation
Partial or hypomethylation of MXI1 was primarily observed in G3 and G4 medulloblastomas, whilst hypomethylation of IL8 was most commonly observed in the WNT and SHH subgroups (Fig. 4) . Significant relationships between array and bisulfite sequencing estimations of methylation status were observed for both MXI1 (linear, Spearman's q = 0.79, p = 8.3 9 10 -9 ) and IL8 (exponential, Spearman's q = 0.83, p = 2.5 9 10 -10 ), and their methylation at the array-assessed CpG residues reflected wider methylation patterns at adjacent CpG residues (Supplementary Figure S5) .
Incorporation of DNA methylation markers significantly improves medulloblastoma riskstratification models
Finally, we derived a novel risk-classification scheme which provides precedent for how DNA methylation biomarkers could form the basis of improved disease prognostication. Each risk factor (M? disease, LCA histology, MYC family amplification, and binary methylation of IL8 and MXI1), conferred approximately equivalent hazards (ratios 2.79-4.09) in Cox models of non-WNT medulloblastomas ( Fig. 4; Supplementary Figure S6 ). Based on their even risk distribution, a risk-stratification model was tested whereby non-WNT patients with B1 risk factor were classified as favorable risk, 2 risk factors as standard risk and C3 risk factors as poor risk. All WNT tumors were classified as favorable risk. This model achieved a significantly superior prediction of outcome (AUC = 0.799 at 5 years, p = 4.7 9 10 -11 ) compared to both current clinical stratification (AUC = 0.677, p = 0.0001) and clinical/molecular schema (AUC = 0.718, p = 1.9 9 10 -6 ) which will form the basis of the forthcoming PNET5 clinical trial [14, 37] (Fig. 5) . The addition of MXI1 and IL8 DNA methylation biomarkers enabled classification of 46 % of patients as favorable risk (5-year PFS 92 %, 95 % CI 86-98 %), compared to 13 % in Fig. 3 Gene-specific DNA methylation differences between medulloblastoma subgroups. The top five most significant hyper-and hypomethylation changes associated with each subgroup (methylated red, unmethylated green, partially methylated black). For each probe, gene name, position (P promoter region, E exonic region, number is distance from transcriptional start site) and BH corrected p values assessed by Mann-Whitney U tests, are shown the PNET5 model (5-year PFS 95 %, 95 % CI 87-100 %). Likewise, the proportion of high-risk patients is reduced to 16 % (5-year PFS 22 %, 95 % CI 11-43 %) compared to 30 % using the PNET5 model (5-year PFS 43 %, 95 % CI 31-58 %).
Discussion
This first comprehensive investigation of gene-specific DNA methylation profiles in medulloblastoma clearly demonstrates the potential of epigenetics to support advances in clinical management of this heterogeneous disease.
We have shown using cross-validated class-discovery approaches that medulloblastoma comprises four major DNA methylation subgroups. Independent assessments of subgroup status using a range of alternative assays (expression signatures, IHC, mutational and genomic markers) demonstrate a close relationship to previously described gene expression subgroups [7, 22, 32, 48, 51] . Importantly, DNA methylomics allowed the robust discrimination of subgroup status in 95 % (129/136) of FFPE biopsies, independent of sample storage time (9.4-17.1 years; median 13.0) and outperformed transcriptomic methods (68 % FFPE biopsies classifiable [33] ). This offers distinct advantages for the subclassification of patients in routine practice or from archival cohorts. As a proof-of-concept, we identified minimal signatures capable of identifying disease subgroups (65-probe signature) and assigning WNT subgroup membership (5 probes) (Supplementary Methods, Supplementary Figs. 7, 8 and 9 ) which demonstrate how diagnostic methylation signatures could be applied in clinical assay development. Finally, a subset of samples (*6 %; frozen and FFPE biopsies) could not be classified confidently, indicating recognition of molecular 'non-classified' patients may be important for accurate definition of clinical and molecular associations. Further investigations will be required to determine whether these represent true biological effects or technical (e.g. sample/assay) limitations. Subgroup-specific DNA methylation events were more common than DNA sequence mutations reported in recent whole-genome mutational studies [19, 35, 38, 40] . Our data identify candidate epigenetic events with potential roles in tumorigenesis, particularly in the poorly characterized Groups 3 and 4, and any role(s) in the disease, or as a basis for future therapies, now need to be considered. While the genome-wide approach to assay DNA methylation used in this study does not lend itself to direct comparison with previous candidate gene-driven studies of methylation in medulloblastoma, the previously reported relationship between desmoplastic/nodular pathology and COL1A2 methylation [1] was also observed in our data set (p = 1.4 9 10 -5 , v 2 test). Our study is distinguished by its use of a centrally reviewed, trials-based cohort to make assessments of molecular events, subgroup status and prognostic relationships using high-throughput data. In this group of non-infant patients (3-16 years at diagnosis), only WNT patients displayed significantly different outcomes. Despite reports from recent retrospective studies in group-wide medulloblastoma cohorts [7, 32] , Group 3 patients did not have a worse outcome in our cohort, consistent with a recent retrospective meta-analysis of seven independent studies, which showed survival equivalence for all non-WNT subgroups in non-infant patients aged 4-16 at diagnosis [21] . Group 3 tumors were associated with a poor prognosis in infant patients \4 years of age at diagnosis in this metaanalysis [21] , suggesting any overall survival differences for Group 3 tumors may be influenced by patient age or treatment received; these observations now require further examination in large, clinically controlled studies. We demonstrate here that addition of DNA methylation biomarkers significantly improves survival prediction for non-WNT medulloblastomas arising in patients aged 3-16 at diagnosis. Incorporation of MXI1 and IL8 methylation status alongside currently used molecular, pathological and clinical variables [37] markedly improved stratification of disease risk. Almost half of patients (46 %) could be assigned to a favorable-risk group ([90 % 5-year PFS) and could potentially be considered for therapy de-escalation aimed at reduced late effects, whilst the most intensive therapies could potentially now be limited to a much smaller group of high-risk patients (16 %; 22 % 5-year PFS). The biomarker discovery and validation strategies employed here used case resampling and cross-validation to prevent overfitting of risk models, to give an unbiased estimate of prognostic performance according to best practice as outlined by Simon and Subramanian [46] . Our methodologies conformed to the REMARK criteria for novel biomarker development [29] , including the validation of array-based findings using alternative methods (bisulfite sequencing). The powerful performance of MXI1 and IL8 as novel prognostic biomarkers selected from initial highdimensional data sets suggests that future discoveries using emerging higher-resolution DNA methylation analysis technologies will pay further dividends.
IL8
MXI1 is a negative regulator of the MYC family of proteins [53] . We have previously reported its allelic loss and mutation [45] , and MXI1 methylation may represent an additional mechanism for the disruption of MYC pathways in medulloblastoma [5] . MXI1 methylation was not associated with membership of Group 3, LCA disease or MYC amplification in our study (data not shown). Likewise, IL8 has potential involvement in chemokine signaling and angiogenic processes in tumor development [31] . Thus, although outside the scope of the present study, the functional contributions of MXI1 and IL8 to medulloblastoma tumorigenesis and clinical behavior now require urgent investigation.
In summary, we have demonstrated that DNA methylation profiling enables the robust subclassification of four disease subgroups in frozen and routinely collected or archival FFPE biopsy material. Moreover, we show that incorporation of DNA methylation biomarkers can significantly improve upon current disease-risk stratification schemes. These findings have important implications for future risk-adapted clinical disease management in medulloblastoma.
